StockNoteStockNote
Lam Dong - Ladophar Pharmaceutical Joint Stock Company (LDP) was established in 1982 on the basis of merging district and town pharmaceutical companies into Lam Dong Union Pharmaceutical Enterprise. In 1999, the Company equitized, becoming the first equitized local pharmaceutical company in the country. The Company's business activities focus on trading and trading in medicinal products for human health. The company's products are diverse with more than 1. 000 types of drugs, including conventional and specialty drugs. These products are supplied from two main sources: direct import of special drugs from abroad and domestic drug supply. Own Actiso material area and other precious medicinal materials meeting GACP-WHO international standards. LDP's production system ensures a one-way line from raw materials, auxiliary materials, factory area and warehouse of more than 10,000 m2 in Lam Dong. Capacity reached about 800 tons of herbal tea, 180 tons of soft high, 180 tons of dry high a year...On July 20, 2010, LDP officially traded on the Hanoi Stock Exchange (HNX).
LDP currently has a market capitalization of roughly VND 148 billion, placing it in the small-cap group on the Vietnamese stock market. Its current P/E of 5,2x is 60% below its own 5-year average (12,9x), suggesting the stock is trading cheaper than its historical norm. P/B stands at 0,7x, 54% below its multi-year average of 1,6x. Return on equity (ROE) is at 16,1%, down from 23,4% the year before. Its debt-to-equity ratio of 0,3x is low, reflecting a conservative capital structure. In 2025, revenue grew 12% year-on-year while after-tax profit grew 313%.
This note is generated automatically from the stock's real financial data, for reference only — not investment advice.
Unit: VND billion. Growth (%) vs. previous period.
Unit: VND billion. Year-end values; current year uses latest session.
Unit: x. Financial debt over shareholders' equity.
Data aggregated from cafef.vn and VNDirect, for reference only, not investment advice.